Alvotech (ALVO) Change in Account Payables (2021 - 2026)
Alvotech (ALVO) posted Change in Account Payables of -$34.3 million for Q1 2026, down 146.88% on a QoQ basis from $73.2 million in Q4 2025, and down 1001.76% year-over-year from $3.8 million in Q1 2025.
Alvotech (ALVO) Change in Account Payables (2021 - 2026) Analysis & Trends
Alvotech's Change in Account Payables history runs 6 years deep, the most recent figure standing at -$34.3 million for Q1 2026.
- Quarterly Change in Account Payables fell 1001.76% year-over-year to -$34.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (up 180.53% YoY) and the FY2025 annual result came in at $45.3 million, up 430.87% from the prior year.
- Change in Account Payables was -$34.3 million for Q1 2026 at Alvotech, down from $73.2 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $73.2 million in Q4 2025 and bottomed at -$45.7 million in Q3 2025.
- A 5-year average of $1.3 million and a median of $6.6 million in 2022 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2025 — Change in Account Payables soared 634.86% — and 2026, when it slumped 1001.76%.
- Alvotech's Change in Account Payables stood at $6.6 million in 2022, then surged by 393.11% to $32.3 million in 2023, then plunged by 142.35% to -$13.7 million in 2024, then surged by 634.86% to $73.2 million in 2025, then slumped by 146.88% to -$34.3 million in 2026.
- Business Quant data shows ALVO's Change in Account Payables at -$34.3 million in Q1 2026, $73.2 million in Q4 2025, and -$45.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 23.15 Bn | 20.99 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.51 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.42 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | - |
| 10 | Alvotech | 924.39 Mn | 924.39 Mn | 5.09 Mn | -34.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.34 Mn |
| Mar 31, 2026 | -34.34 Mn |
| Dec 31, 2025 | 73.25 Mn |
| Dec 31, 2025 | 73.25 Mn |
| Sep 30, 2025 | -45.69 Mn |
| Sep 30, 2025 | -45.69 Mn |
| Jun 30, 2025 | 13.95 Mn |
| Jun 30, 2025 | 13.95 Mn |
| Mar 31, 2025 | 3.81 Mn |
| Mar 31, 2025 | 3.81 Mn |
| Dec 31, 2024 | -13.70 Mn |
| Dec 31, 2024 | -13.70 Mn |
| Sep 30, 2024 | -6.18 Mn |
| Sep 30, 2024 | -6.18 Mn |
| Jun 30, 2024 | 7.17 Mn |
| Jun 30, 2024 | 7.17 Mn |
| Mar 31, 2024 | -28.93 Mn |
| Mar 31, 2024 | -28.93 Mn |
| Dec 31, 2023 | 32.34 Mn |
| Dec 31, 2023 | 32.34 Mn |